PURPOSE: We undertook a meta-analysis of randomized trials to evaluate the efficacy of multitargeted antiangiogenic tyrosine kinase inhibitors (MATKIs) in addition to chemotherapy in metastatic breast cancer. METHODS: PubMed, Web of Knowledge databases and the ASCO meeting abstracts were searched for eligible literature published up to August 30, 2013. The endpoints included progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and toxicities. Pooled hazard ratios (HRs) for survival outcomes and odds ratio (ORs) for dichotomous data with 95 % confidence intervals (CIs) were derived. RESULTS: Eight studies including 2,077 participants were analyzed. Compared to chemotherapy alone, adding MATKIs to chemotherapy resulted in a 14 % risk reduction of PFS events. However, the benefit did not reach statistical significance (HR 0.86; 95 % CI 0.70-1.04, P=0.126). Also, no OS benefit was observed (HR 1.03; 95 % CI 0.89-1.18, P=0.724). The addition of MATKIs significantly increased the ORR (OR 1.57; 95 % CI 1.30-1.91, P=0.000). Subgroup analysis revealed that sorafinib showed a significantly greater effect on PFS in patients with HER2 negative metastatic breast cancer (HR 0.67; 95 % CI 0.55-0.82, P=0.000) in comparison to chemotherapy alone. Additionally, sunitinib seemed to have no substantial efficacy for metastatic breast cancer. Toxicities were more frequent in patients receiving MATKIs. CONCLUSION: Overall, regimens consisting of MATKIs seemed not to be superior to chemotherapy alone in terms of PFS and OS, although significant improvement in ORR was observed. However, the addition of sorafenib significantly improved PFS. Further studies are needed to corroborate this finding.
PURPOSE: We undertook a meta-analysis of randomized trials to evaluate the efficacy of multitargeted antiangiogenic tyrosine kinase inhibitors (MATKIs) in addition to chemotherapy in metastatic breast cancer. METHODS: PubMed, Web of Knowledge databases and the ASCO meeting abstracts were searched for eligible literature published up to August 30, 2013. The endpoints included progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and toxicities. Pooled hazard ratios (HRs) for survival outcomes and odds ratio (ORs) for dichotomous data with 95 % confidence intervals (CIs) were derived. RESULTS: Eight studies including 2,077 participants were analyzed. Compared to chemotherapy alone, adding MATKIs to chemotherapy resulted in a 14 % risk reduction of PFS events. However, the benefit did not reach statistical significance (HR 0.86; 95 % CI 0.70-1.04, P=0.126). Also, no OS benefit was observed (HR 1.03; 95 % CI 0.89-1.18, P=0.724). The addition of MATKIs significantly increased the ORR (OR 1.57; 95 % CI 1.30-1.91, P=0.000). Subgroup analysis revealed that sorafinib showed a significantly greater effect on PFS in patients with HER2 negative metastatic breast cancer (HR 0.67; 95 % CI 0.55-0.82, P=0.000) in comparison to chemotherapy alone. Additionally, sunitinib seemed to have no substantial efficacy for metastatic breast cancer. Toxicities were more frequent in patients receiving MATKIs. CONCLUSION: Overall, regimens consisting of MATKIs seemed not to be superior to chemotherapy alone in terms of PFS and OS, although significant improvement in ORR was observed. However, the addition of sorafenib significantly improved PFS. Further studies are needed to corroborate this finding.
Authors: Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Provencher; Frank Priou; Wolfgang Eiermann; Encarna Adrover; Istvan Lang; Manuel Ramos; Jean Latreille; Agnieszka Jagiełło-Gruszfeld; Tadeusz Pienkowski; Emilio Alba; Raymond Snyder; Sachin Almel; Janusz Rolski; Montserrat Munoz; Rebecca Moroose; Sara Hurvitz; Ana Baños; Henry Adewoye; Yong-Jiang Hei; Mary-Ann Lindsay; Matthieu Rupin; David Cabaribere; Yasmin Lemmerick; John R Mackey Journal: Lancet Oncol Date: 2011-03-21 Impact factor: 41.316
Authors: M Relf; S LeJeune; P A Scott; S Fox; K Smith; R Leek; A Moghaddam; R Whitehouse; R Bicknell; A L Harris Journal: Cancer Res Date: 1997-03-01 Impact factor: 12.701
Authors: José Baselga; José Getúlio Martins Segalla; Henri Roché; Auro Del Giglio; Hélio Pinczowski; Eva M Ciruelos; Sebastião Cabral Filho; Patricia Gómez; Brigitte Van Eyll; Begoña Bermejo; Antonio Llombart; Bernardo Garicochea; Miguel Ángel Climent Durán; Paulo Marcelo Gehm Hoff; Marc Espié; Andre Augusto Junior Gemeinder de Moraes; Ronaldo Albuquerque Ribeiro; Clarissa Mathias; Miguel Gil Gil; Belén Ojeda; Josefa Morales; Sunhee Kwon Ro; Shell Li; Frederico Costa Journal: J Clin Oncol Date: 2012-03-12 Impact factor: 44.544
Authors: A Valachis; N P Polyzos; N Alpha Patsopoulos; V Georgoulias; D Mavroudis; D Mauri Journal: Breast Cancer Res Treat Date: 2010-01-09 Impact factor: 4.872
Authors: Katalin Boér; István Láng; Antonio Llombart-Cussac; Inger Andreasson; Guillermo L Vivanco; Nick Sanders; Gillian M Pover; Elizabeth Murray Journal: Invest New Drugs Date: 2010-09-10 Impact factor: 3.850